-
-
-
-
-
-
-
RBC Capital Starts Aardvark Therapeutics Inc (AARD) at Outperform
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
-
-
-
-
-
-
Crinetics (CRNX) PT Lowered to $91 at Citizens JMP
-
-
-
-
-
-
-
Precigen Inc. (PGEN) Granted FDA Priority Review for PRGN-2012
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) PT Raised to $35 at Citi
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) PT Raised to $60 at TD Cowen Following FDA Acceptance and Priority Review for Vatiquinone NDA
-
-
-
-
-
-
-
Gilead Sciences (GILD): U.S. FDA Accepts New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
-
13,589 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All